US Stock MarketDetailed Quotes

Chemomab Therapeutics (CMMB)

Watchlist
  • 1.670
  • +0.011+0.66%
Trading Apr 22 12:29 ET
12.02MMarket Cap-1.16P/E (TTM)

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Chemomab Therapeutics (CMMB) Income Statement

Quarterly+Annual
YOY yoy
Hide blank lines yoy
(FY)Dec 31, 2025
(Q4)Dec 31, 2025
(Q3)Sep 30, 2025
(Q2)Jun 30, 2025
(Q1)Mar 31, 2025
(FY)Dec 31, 2024
(Q4)Dec 31, 2024
(Q3)Sep 30, 2024
(Q2)Jun 30, 2024
(Q1)Mar 31, 2024
Total revenue
0
0
0
0
0
0
0
0
0
0
Operating revenue
--0
--0
--0
--0
--0
--0
--0
--0
--0
--0
Cost of revenue
Gross profit
Operating expense
-35.09%9.57M
-38.56%1.97M
-50.30%1.84M
-39.97%2.26M
-13.86%3.49M
-42.11%14.74M
-16.50%3.21M
-15.04%3.71M
-54.02%3.77M
-55.27%4.05M
Selling and administrative expenses
9.44%3.73M
9.85%881K
1.14%884K
16.07%975K
10.94%994K
-51.79%3.41M
6.79%802K
-11.72%874K
-73.54%840K
-58.56%896K
-General and administrative expense
9.44%3.73M
9.85%881K
1.14%884K
16.07%975K
10.94%994K
-51.79%3.41M
6.79%802K
-11.72%874K
-73.54%840K
-58.56%896K
Research and development costs
-48.50%5.83M
-54.67%1.09M
-66.15%960K
-56.05%1.29M
-20.91%2.49M
-38.38%11.33M
-22.15%2.41M
-16.02%2.84M
-41.67%2.93M
-54.23%3.15M
Operating profit
35.09%-9.57M
38.56%-1.97M
50.30%-1.84M
39.97%-2.26M
13.86%-3.49M
42.11%-14.74M
16.50%-3.21M
15.04%-3.71M
54.02%-3.77M
55.27%-4.05M
Net non-operating interest income expense
-27.96%572K
-59.60%101K
-55.07%102K
49.64%205K
-8.89%164K
-35.86%794K
-42.00%250K
-1.73%227K
-47.10%137K
-43.22%180K
Non-operating interest income
-27.96%572K
----
----
----
----
-35.86%794K
----
----
----
----
Total other finance cost
----
----
55.07%-102K
-49.64%-205K
8.89%-164K
35.86%-794K
42.00%-250K
1.73%-227K
47.10%-137K
43.22%-180K
Other net income (expense)
Income before tax
35.50%-9M
36.79%-1.87M
49.99%-1.74M
43.35%-2.06M
14.09%-3.32M
42.43%-13.95M
13.29%-2.96M
15.79%-3.48M
54.25%-3.63M
55.70%-3.87M
Income tax
0
0
0
0
0
0
0
0
0
Net income
35.50%-9M
36.79%-1.87M
49.99%-1.74M
43.35%-2.06M
14.09%-3.32M
42.43%-13.95M
13.29%-2.96M
14.65%-3.48M
54.44%-3.63M
55.81%-3.87M
Net income continuous Operations
35.50%-9M
36.79%-1.87M
49.99%-1.74M
43.35%-2.06M
14.09%-3.32M
42.43%-13.95M
13.29%-2.96M
14.65%-3.48M
54.44%-3.63M
55.81%-3.87M
Minority interest income
Net income attributable to the parent company
35.50%-9M
36.79%-1.87M
49.99%-1.74M
43.35%-2.06M
14.09%-3.32M
42.43%-13.95M
13.29%-2.96M
14.65%-3.48M
54.44%-3.63M
55.81%-3.87M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders
35.50%-9M
36.79%-1.87M
49.99%-1.74M
43.35%-2.06M
14.09%-3.32M
42.43%-13.95M
13.29%-2.96M
14.65%-3.48M
54.44%-3.63M
55.81%-3.87M
Basic earnings per share
53.85%-1.44
62.50%-0.24
60.00%-0.32
69.23%-0.32
50.00%-0.56
62.14%-3.12
27.27%-0.64
41.18%-0.8
63.89%-1.04
65.00%-1.12
Diluted earnings per share
53.85%-1.44
62.50%-0.24
60.00%-0.32
69.23%-0.32
50.00%-0.56
62.14%-3.12
27.27%-0.64
41.18%-0.8
63.89%-1.04
65.00%-1.12
Dividend per share
Currency Unit
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
Accounting Standards
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
Audit Opinions
Unqualified Opinion with Explanatory Notes
--
--
--
--
Unqualified Opinion with Explanatory Notes
--
--
--
--
(FY)Dec 31, 2025(Q4)Dec 31, 2025(Q3)Sep 30, 2025(Q2)Jun 30, 2025(Q1)Mar 31, 2025(FY)Dec 31, 2024(Q4)Dec 31, 2024(Q3)Sep 30, 2024(Q2)Jun 30, 2024(Q1)Mar 31, 2024
Total revenue 0000000000
Operating revenue --0--0--0--0--0--0--0--0--0--0
Cost of revenue
Gross profit
Operating expense -35.09%9.57M-38.56%1.97M-50.30%1.84M-39.97%2.26M-13.86%3.49M-42.11%14.74M-16.50%3.21M-15.04%3.71M-54.02%3.77M-55.27%4.05M
Selling and administrative expenses 9.44%3.73M9.85%881K1.14%884K16.07%975K10.94%994K-51.79%3.41M6.79%802K-11.72%874K-73.54%840K-58.56%896K
-General and administrative expense 9.44%3.73M9.85%881K1.14%884K16.07%975K10.94%994K-51.79%3.41M6.79%802K-11.72%874K-73.54%840K-58.56%896K
Research and development costs -48.50%5.83M-54.67%1.09M-66.15%960K-56.05%1.29M-20.91%2.49M-38.38%11.33M-22.15%2.41M-16.02%2.84M-41.67%2.93M-54.23%3.15M
Operating profit 35.09%-9.57M38.56%-1.97M50.30%-1.84M39.97%-2.26M13.86%-3.49M42.11%-14.74M16.50%-3.21M15.04%-3.71M54.02%-3.77M55.27%-4.05M
Net non-operating interest income expense -27.96%572K-59.60%101K-55.07%102K49.64%205K-8.89%164K-35.86%794K-42.00%250K-1.73%227K-47.10%137K-43.22%180K
Non-operating interest income -27.96%572K-----------------35.86%794K----------------
Total other finance cost --------55.07%-102K-49.64%-205K8.89%-164K35.86%-794K42.00%-250K1.73%-227K47.10%-137K43.22%-180K
Other net income (expense)
Income before tax 35.50%-9M36.79%-1.87M49.99%-1.74M43.35%-2.06M14.09%-3.32M42.43%-13.95M13.29%-2.96M15.79%-3.48M54.25%-3.63M55.70%-3.87M
Income tax 000000000
Net income 35.50%-9M36.79%-1.87M49.99%-1.74M43.35%-2.06M14.09%-3.32M42.43%-13.95M13.29%-2.96M14.65%-3.48M54.44%-3.63M55.81%-3.87M
Net income continuous Operations 35.50%-9M36.79%-1.87M49.99%-1.74M43.35%-2.06M14.09%-3.32M42.43%-13.95M13.29%-2.96M14.65%-3.48M54.44%-3.63M55.81%-3.87M
Minority interest income
Net income attributable to the parent company 35.50%-9M36.79%-1.87M49.99%-1.74M43.35%-2.06M14.09%-3.32M42.43%-13.95M13.29%-2.96M14.65%-3.48M54.44%-3.63M55.81%-3.87M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders 35.50%-9M36.79%-1.87M49.99%-1.74M43.35%-2.06M14.09%-3.32M42.43%-13.95M13.29%-2.96M14.65%-3.48M54.44%-3.63M55.81%-3.87M
Basic earnings per share 53.85%-1.4462.50%-0.2460.00%-0.3269.23%-0.3250.00%-0.5662.14%-3.1227.27%-0.6441.18%-0.863.89%-1.0465.00%-1.12
Diluted earnings per share 53.85%-1.4462.50%-0.2460.00%-0.3269.23%-0.3250.00%-0.5662.14%-3.1227.27%-0.6441.18%-0.863.89%-1.0465.00%-1.12
Dividend per share
Currency Unit USDUSDUSDUSDUSDUSDUSDUSDUSDUSD
Accounting Standards US-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions Unqualified Opinion with Explanatory Notes--------Unqualified Opinion with Explanatory Notes--------
Market Insights
No. Symbol 20D % Chg
Sample Name
Sample Code
 +15.81%
Sample Name
Sample Code
 +13.87%
Sample Name
Sample Code
 +7.86%
4
ProShares Ultra Bloomberg Crude Oil ETF
UCO
+4.51%
5
United Sts 12 Month Oil Fd Lp Unit Ben Int
USL
+3.04%
View More
China Concept Stocks
No. Symbol 5D % Chg
Sample Name
Sample Code
 +26.78%
Sample Name
Sample Code
 +26.75%
Sample Name
Sample Code
 +9.58%
4
Atour Lifestyle Holdings
ATAT
+7.51%
5
Chagee Holdings
CHA
+4.97%
View More
Middle East conflict spreads to the stock market! How should investors respond?
On April 22 Beijing time, reports indicated that Trump agreed to extend the ceasefire between the US and Iran by 3-5 days rather than indefi Show More
Long-term answers | Your account on the left shrinks, while your right hand is chased by the times — Be the person that no bombardment can ever wipe out.
Hormuz, Term Structure and USO: Navigating the Energy Storm

- No more -